SSY GROUP Receives Regulatory Approval for Ziprasidone Mesylate as API for Commercial Pharmaceutical Use

Stock News

Yesterday

SSY GROUP (stock code: 02005) has announced that its Ziprasidone Mesylate has been granted registration approval by China's National Medical Products Administration, enabling its use as an active pharmaceutical ingredient (API) in marketed drug formulations.

This API is primarily indicated for treating acute agitation symptoms in patients with schizophrenia. The newly obtained approval further strengthens the company's portfolio of second-generation antipsychotic high-potency active pharmaceutical ingredients (HPAPI).

Currently, the group has established a leading domestic platform for second-generation antipsychotic HPAPIs, encompassing Blonanserin, Lurasidone, Ziprasidone Hydrochloride, and the newly approved Ziprasidone Mesylate. This development consistently provides robust supply chain support for domestic pharmaceutical manufacturers seeking high-quality APIs.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/news/1137116463"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1137116463\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1137116463?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-16 17:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137116463","market":"sg","top_or_hot":-1,"title":"SSY GROUP Receives Regulatory Approval for Ziprasidone Mesylate as API for Commercial Pharmaceutical Use","media":"Stock News","content":"<p><b>SSY GROUP</b> (<b>stock code: 02005</b>) has announced that its Ziprasidone Mesylate has been granted registration approval by China's National Medical Products Administration, enabling its use as an active pharmaceutical ingredient (API) in marketed drug formulations.<br><br>This API is primarily indicated for treating acute agitation symptoms in patients with schizophrenia. The newly obtained approval further strengthens the company's portfolio of second-generation antipsychotic high-potency active pharmaceutical ingredients (HPAPI).<br><br>Currently, the group has established a leading domestic platform for second-generation antipsychotic HPAPIs, encompassing Blonanserin, Lurasidone, Ziprasidone Hydrochloride, and the newly approved Ziprasidone Mesylate. This development consistently provides robust supply chain support for domestic pharmaceutical manufacturers seeking high-quality APIs.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SSY GROUP Receives Regulatory Approval for Ziprasidone Mesylate as API for Commercial Pharmaceutical Use</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSSY GROUP Receives Regulatory Approval for Ziprasidone Mesylate as API for Commercial Pharmaceutical Use\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-16 17:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>SSY GROUP</b> (<b>stock code: 02005</b>) has announced that its Ziprasidone Mesylate has been granted registration approval by China's National Medical Products Administration, enabling its use as an active pharmaceutical ingredient (API) in marketed drug formulations.<br><br>This API is primarily indicated for treating acute agitation symptoms in patients with schizophrenia. The newly obtained approval further strengthens the company's portfolio of second-generation antipsychotic high-potency active pharmaceutical ingredients (HPAPI).<br><br>Currently, the group has established a leading domestic platform for second-generation antipsychotic HPAPIs, encompassing Blonanserin, Lurasidone, Ziprasidone Hydrochloride, and the newly approved Ziprasidone Mesylate. This development consistently provides robust supply chain support for domestic pharmaceutical manufacturers seeking high-quality APIs.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1137116463","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137116463","pubTimestamp":1789549471,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"SSY GROUP (stock code: 02005) has announced that its Ziprasidone Mesylate has been granted registration approval by China's National Medical Products Administration, enabling its use as an active...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","LU2460026573.USD":"abrdn SICAV I -  CHINA NEXT GENERATION \"A\" (USD) ACC","02005":"石四药集团","IPOS":"Renaissance International IPO ETF"},"translate_title":"SSY集团甲磺酸齐拉西酮作为商业制药原料药获得监管部门批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02005":1,"IPOS":1},"content_text":"SSY GROUP (stock code: 02005) has announced that its Ziprasidone Mesylate has been granted registration approval by China's National Medical Products Administration, enabling its use as an active pharmaceutical ingredient (API) in marketed drug formulations.This API is primarily indicated for treating acute agitation symptoms in patients with schizophrenia. The newly obtained approval further strengthens the company's portfolio of second-generation antipsychotic high-potency active pharmaceutical ingredients (HPAPI).Currently, the group has established a leading domestic platform for second-generation antipsychotic HPAPIs, encompassing Blonanserin, Lurasidone, Ziprasidone Hydrochloride, and the newly approved Ziprasidone Mesylate. This development consistently provides robust supply chain support for domestic pharmaceutical manufacturers seeking high-quality APIs.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}